Pharmacoeconomic considerations of tropisetron for prophylaxis and treatment of CINV and PONV

References

• Kapur PA. Editorial: the big little problem. Anesth Anal 73,243–245 (1991).
   PubMed Web of Science ®Google Scholar
• Gan TJ, Sloan F, de L Dear G, El-Moalem HE, Lubarsky DA. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth. Analg: 92,393–400 (2001).
   Google Scholar
• Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are both common and important to avoid? The perspective of patients. Anesth. Analg: 89,652–658 (1999).
   PubMed Web of Science ®Google Scholar
• Gold BS, Kitz DS, Lecky JH, Neuhaus JM. Unanticipated admission to the hospital following ambulatory surgery. J4/V/A 262, 3008–3010 (1989).
   Google Scholar
• Meeks GR, Waller GA, Meydrech EF, Flautt FH Jr. Unscheduled hospital admission following ambulatory gynecologic surgery. Obstet. Cynecol 80, 446–450 (1992).
   Google Scholar
• Watcha NW, Smith I. Cost-effectiveness analysis of antiemetic therapy for ambulatory surgery. J. Gun. Anesth. 6, 370–377 (1994).
   PubMed Web of Science ®Google Scholar
• Sanchez LA, Hirsch JD. Identification of cost-consequences as the critical step in a cost-of-illness study: postoperative nausea and vomiting in an ambulatory surgery center example. J. Res. Pharm. Econ. 4, 41–53 (1992).
   Google Scholar
• Carroll NV, Miederhoff PA, Cox FM, Hirsch JD. Costs incurred by outpatient surgical centers in managing postoperative nausea and vomiting. J. Gun. Anesth. 6, 364–369 (1994).
   PubMed Web of Science ®Google Scholar
• Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative interview: assessing risk factors for nausea and vomiting. Anesth Anal 78,7–16 (1994).
   PubMed Web of Science ®Google Scholar
• Eberhart LHJ, Seeling W, Roos A, Georgieff M. Comparison of three risk scores to predict postoperative nausea and vomiting. Ear. J. Anaesthesia" 17\(Suppl. 19), A15—A15 (2000).
   Google Scholar
• Apfel CC, Kranke P, Eberhart LHJ, Roos A, Roewer N. Comparison of predictive models for postoperative nausea and vomiting. BE J. Anaesth. 88, 234–240 (2002).
   Google Scholar
• Lee CR, Plosker GL, McTavish D. Topisetron: a review of its pharmacodynamic and pharmakokinetic properities and therapeutic potential as an antiemetic. Drugs 46, 925–943 (1993).
   PubMed Web of Science ®Google Scholar
• Roila F, Ballatori E, Tonato M eta]. 5-HT 3 receptor antagonists: differences and similarities. Eur.j Cancer 33,1364–1370 (1997).
   Google Scholar
• Perez EA. A risk—benefit assessment of 5- HT 3 receptor antagonist in antineoplastic therapy-induced emesis. Drug- Sal 18, 43–56 (1998).
   PubMed Web of Science ®Google Scholar
• de Bruijn KM. Tropisetron: a review of the clinical experience. Drugs 43\(Suppl. 3), 11–22 (1992).
   Google Scholar
• Fischer V, Baldeck J-P, Tse FLS. Pharmakokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single doses in humans. Drug Metab. Dispos. 20, 603–607 (1992).
   Google Scholar
• Novartis Pharma AG: Navoban (tropisetron). Product monography Basel, Switzerland (1998).
   Google Scholar
• Eberhart LHJ, Bernert S, Wulf H, Geldner G. Pharmakoökonomische Modelle zur Kostenberechnung am Beispiel einer Studie zur Prophylaxe von Obelkeit und Erbrechen in der postoperativen Phase. Anaesthesist 51, 475–481 (2002).
   PubMedGoogle Scholar
• •One of only two articles found in the authors' extensive literature research about pharmacoeconomic considerations concerning postoperative nausea and vomiting and thus highly relevant to this review. It contains a cost-effectiveness analysis comparing two different anesthetic models to avoid postoperative nausea and vomiting. One of these models uses an antiemetic prophylaxis with tropisetron and fortecortin.
   Google Scholar
• Eberhart LH, Mauch M, Morin AM, Wulf H, Geldner G. Impact of a multimodal antiemetic prophylaxis on patient satisfaction in high-risk patients for postoperative nausea and vomiting. Anaesthesia 57,1022–1027 (2002).
   Google Scholar
• Eberhart L, Morin AM, Seeling W, Bothner U, Georgieff M. Metaanalyse kontrollierter randomisierter Studien zum Einsatz von. Droperidol zur Prophylaxe von Ubelkeit und Erbrechen in der postoperativen Phase. Anasthesiol Intensivmed Notfallmed Schmerzther 34, 528–536 (1999).
   Google Scholar
• Henzi I, Sonderegger J, Trani& MR. Efficacy, dose-response and adverse effects of droperidol for prevention of postoperative nausea and vomiting. Can. J. Anesth. 47,537–551 (2000).
   Google Scholar
• White PE Droperidol: a cost effective antiemetic for over thirty years. Anesth. Analg: 95,789–790 (2002).
   PubMed Web of Science ®Google Scholar
• Henzi I, Walder B, Trani& MR. Dexamethasone for the prevention of postoperative nausea and vomiting: a quantitative systematic review. Anesth. Analg: 90,186-194 (2000).
   Google Scholar
• Eberhart LHJ, Morin AM, Georgieff. Dexamethason zur prophylaxe von übelkeit und erbrechen in der postoperativen phase. Eine metaanalyse kontrollierter randomisierter studien. Anaesthesist 49, 713–720 (2000).
   Google Scholar
• Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of dexamethasone administration on its efficacy as a prophylactic anti-emetic for postoperative nausea and vomiting. Anesth. Analg: 91, 136–139 (2000).
   PubMed Web of Science ®Google Scholar
• Sung YE Risks and benefits of drugs used in the management of postoperative nausea and vomiting. Drug- Sal 14,181–197 (1996).
   PubMed Web of Science ®Google Scholar
• Kazemi-Kjellberg F, Henzi I, Trani& MR. Treatment of established postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiologyl, (2001).
   Google Scholar
• Eberhart LHJ, Morin AM, Bothner U, Georgieff M. Droperidol im. vergleich zu 5-HT3 antagonist en zur prophylaxe von übelkeit und erbrechen in der postoperativen phase. Eine metaanalyse kontrollierter randomisierter studien. Anásth. Intensivmed 42,58–69 (2001).
   Google Scholar
• Kranke P, Eberhart L, Apfel C, Morin A, Roewer N. Tropisetron zur prophylaxe von übelkeit und erbrechen in der postoperativen phase: eine quantitative systematische übersicht (meta-analyse). Abstractbancl des Deutschen Anásthesiekongresses 2002. 176–176 (2002).
   Google Scholar
• ••The only meta-analysis of tropisetron forthe prophylaxis of postoperative nausea and vomiting in the authors literature search
   Google Scholar
• Diller CM, Weiss M, Gerber AC. Tropisetron zur prophylaxe von postoperativem erbrechen bei kindern. Wirksamkeit und verträglichkeit nach tonsillektomien und adenotonsillektomien. Anaesthesist 49, 275–278 (2000).
   Google Scholar
• Jensen AB, Christiansen DB, Coulthard K et al Tropisetron reduces postoperative vomiting in children undergoing tonsillectomy. Paediatr: Anaesth 10,69–75 (2000).
   PubMedGoogle Scholar
• Henzi I, Walder B, Trani& MR. Metoclopramide in the prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled studies. BE Anaesth. 83,761–771 (1999)
   PubMed Web of Science ®Google Scholar
• Wymenga ANM, van der Graaf WTA, Wits JA et al A randomized, double-blind, multicentre study comparing daily 2 and 5mg of tropisetron for the control of nausea and vomiting induced by low-dose cisplatin or non-cisplatin containing chemotherapy. Ann. Oncol 7,505–510 (1996).
   Google Scholar
• Van Belle SJP, Stamatakis L, Bleiberg H etal Dose-finding study of tropisetron in cisplatin-induced nausea and vomiting. Ann. Oncol. 5,821–825 (1994).
   PubMed Web of Science ®Google Scholar
• Bruntsch U, Drechsler S, Eggert J eta]. Prevention of chemotherapy induced nausea and vomiting by tropisetron (Navoban) alone or in combination with other antiemetic agents. Sernin. Oncol 21, 7–11 (1994).
   Google Scholar
• Drechsler S, Bruntsch U, Eggert J et al Comparision of three tropisetron- containing antiemetic regimens in the prophylaxes of acute and delayed chemotherapy-induced emesis and nausea. Support Cam Cancer 387–395 (1997).
   Google Scholar
• Sorbe B, Anderson H, Schmid M eta]. Tropisetron (Navoban) in the prevention of chemotherapy-induced nausea and vomiting — the Nordic experience. Support Cam Cancer 2,393–399 (1994).
   PubMedGoogle Scholar
• •Covers work from a research group that concentrated on the efficacy of tropisetron for the prophylaxis and treatment of chemotherapy induced nausea and vomiting.
   Google Scholar
• Falkson CI, Falkson HC. Anti-emetic efficacy of tropisetron in patients failing previous anti-emetic therapy. Oncology52, 427–431 (1995).
   PubMed Web of Science ®Google Scholar
• Bleiberg H, Hutstaert F, Buyse M etal Tropisetron in the prevention of acute and delayed nausea and vomiting over six courses of emetogenic chemotherapy. Anticancer Drugs 9,773–777 (1998).
   PubMed Web of Science ®Google Scholar
• The Nordic Anti-emetic Trial Group, Sorbe BG, Hogberg T et al Navoban (tropisetron) alone or in combination with dexamethason in the prevention of chemotherapy induced nausea and vomiting: the nordic experience. Anticancer Drugs 6\(Suppl. 1), 3–6 (1995).
   Google Scholar
• de Wit R, Schmitz PIM, Verweij J etal Analysis of cumulative probalities shows that the efficacy of 5-HT3 antagonist prophylaxis is not maintained. J. Gun. Oncol 14,644–651 (1996).
   Google Scholar
• Cunningham D, Dicato M, Verweij J etal Optimum antiemetic therapy for cisplatin-induced emesis over repeat courses: ondansetron plus dexamathason compared with metoclopramid, dexamethason plus lorazepam. Ann. Oncol 7,277–282 (1996).
   PubMedGoogle Scholar
• IGAR: difference in persistence of efficacy of two antiemeticregimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research. J. Gun. Oncol 11, 2396–2404 (1993).
   Google Scholar
• Del Favero A, Roila E MT Reducing chemotherapy induced nausea and vomiting. Current perspectives and future possibilities. Drug • Sal 9,410–28 (1993).
   Google Scholar
• Chang T-C, Hsieh F, Lai C-H etal Comparision of the efficacy of tropisetron versus a metoclopramide cocktail based on the intensity of cisplatin-induced emesis. Cancer Chemother. Pharmacol 37, 279–285 (1996).
   PubMed Web of Science ®Google Scholar
• Chua DTT, Sham JST, Au GKH etal The antiemetic efficacy of tropisetron plus dexamethason as compared with conventional metoclopramide-dexamethason combination in Orientals recieving cisplatin chemotherapy: a randomized crossover trial. BE j Gun. Pharmacol 41,403–408 (1996).
   Web of Science ®Google Scholar
• Lauria R, Palmieri G, Pepe R et al Comparision of tropisetron (ICS 205-930) with alizapride plus dexamethason in the prevention of emesis induced by repeated cisplatin-containing chemotherapy. Drug Invest. 8,162–169 (1994).
   Google Scholar
• Madej G, Krzakowski M, Pawinski A etal. A comparative study of the use of navoban (ICS 205–930), a 5-HT3 antagonist versus a standard anti-emetic regimen of dexamethasonead metoclopramide in the treatment of cisplatin-containing chemotherapy. Drug- Invest. 6,162-169 (1993).
   Google Scholar
• Sorbe BG, Hogberg T, Glimelius B etal A randomized multicenter study comparing the efficacy and tolerability of tropisetron, a new 5-HT3 receptor antagonist, with a metoclopramidde-containing cocktail in the prevention of cisplatin-induced emesis. Cancer 15,445–454 (1994).
   Google Scholar
• Anderson H, Thatcher N, Howell A et al Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting. Eur. j Cancer 36, 610–615 (1994).
   Google Scholar
• Bruntsch U, Rafenacht E, Parker I et al Tropisetron in the prevention of chemotherapy-induced nausea and vomiting in patients responding poorly to previous conventional antiemetic therapy. Ann. Oncol 4 (Suppl. 3), 25–29 (1993).
   Google Scholar
• Malik I, Moid I, Khan Z etal Prospective randomized comparision of tropisetron with and without dexamethason against high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Am j Gun. Oncol 22,126–130 (1999).
   PubMedGoogle Scholar
• Tejedor I, Idoate A, Jimenez M etal Cost- effectiveness analysis of tropisetron vs. chlorpromazine—dexamethasone in the control of acute emesis induced by highly emetogenic chemotherapy in children. Pharm. World Sc]. 21,60–68 (1999).
   Google Scholar
• Jantunen IT, Kataja VV, RT J. Odansetron and tropisetron with dexamethasone in the prophylaxis of acute vomiting induced by noncisplatin containing chemotherapy. Acta. Onto]. 31,573–575 (1992).
   Google Scholar
• Mantovani G, Maccid A, Bianchi A etal Comparision of granisetron, odansetron and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. Cancer77, 941–948 (1996).
   PubMed Web of Science ®Google Scholar
• Zaluski J, Puistola U, G M eta]. Ondansetron plus dexamethasone, ondansetron and tropisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre, double-blind, randomised, parallel group study. Eur Clin. Res. 9,21-31 (1997).
   Google Scholar
• Jantunen IT, Muhonen TT, Kataja VV etal 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy — a randomised study. Eur j Cancer 29, 1669–1672 (1993).
   Web of Science ®Google Scholar
• Yalci S, Tekuzman G, Baltali E etal Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy. Am. j Clin. 0=1 22, 94–96 (1999).
   Google Scholar
• Massidda B, MT. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT-3-receptor-antagonist in moderately emetogenic chemotherapy. j Chemother. 237–242 (1996).
   Google Scholar
• Aapro MS, Selak M, Lichinitser M etal Palonosetron is more effective than ondansetron in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy: results of a Phase III trial. PASCO2003. 2918 (2003).
   Google Scholar
• Marty M, Kleisbauer J-P, Foumel P etal Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? Anticancer Drugs6(Suppl. 1), 15–21 (1995).
   Google Scholar
• Barrajon E, R d1P. Randomised double- blind crossover study comparing ondansetron, granisetron and tropisetron. A cost—benefit analysis. Support Care Cancer 323–333 (2000).
   Google Scholar
• ••Highly relevant to this review since itssubject is a cost—benefit analysis comparing odansetron, granisetron and tropisetron for the prevention of chemotherapy-induced nausea and vomiting.
   Google Scholar
• Adams M, Soukop M, Barley V etal Tropisetron alone or in combination with dexamethason in the prevention and treatment of emesis induced by noncisplatin chemotherapy: a randomized trial. Anticancer Drugs 6,514–521 (1995).
   PubMed Web of Science ®Google Scholar
• Kris MG, Baltzer L, Pisters KM etal Enhancing the effectiveness of the specific serotonin antagonists. Combination anti-emetic therapy with dexamethasone. Cancer 72,3436–3442 (1993).
   Google Scholar
• Garcia-del-Muro X, Vadell C, Perez-Manga G etal Randomized double-blind study comparing tropisetron alone and in combinationwith dexamethason in the prevention of acute and delayed cisplatin-induced emesis. Eur.j Cancer34,193–195 (1998).
   PubMed Web of Science ®Google Scholar
• Kris MG, Gralla RJ, Tyson LB etal Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone and metoclopramide plus dexamethasone in patients recieving cisplatin. Glitz Chrol7, 108–114 (1989).
   Google Scholar
• Navari RM, Madajewicz S, Anderson N etal Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, randomized comparative trial of ondansetron versus placebo. j Clin. 0=1 13,2408-2416 (1995).
   Google Scholar
• Latreille J, Pater J, Johnson D etal Use of dexamethason and granisetron in the control of delayed emesis for patients who recieved highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trial Group. j Clin. 0=1 1174–1178 (1998).
   Google Scholar
• Gebbia V, Testa A, Valenza R etal Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial. Cancer76, 1821–1828 (1995).
   Google Scholar
• Gridelli C, Lanniello GP, Ambrosia G etal. Ondansetron versus ondansetron plus dexamethasone in the prophylaxis of delayed emesis over three courses of cisplatin chemotherapy: results of a double-blind randomized study. Roc ASC015, 545 (1996).
   Google Scholar
• IGAR. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin induced delayed emesis. The Italian Group for Antiemetic Research. Clin. Onto]. 15,124–130 (1997).
   PubMed Web of Science ®Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ etal Reduction of cisplatin-induced emesis by a selective neurokinin-l-receptor antagonist. L-754,030 Antiemetic Trial Group. N Engl. Med. 340,190-195 (1999).
   Google Scholar
• Sorbe BG, Berglind A-M, Andersson H etal A study evaluating the efficacy and tolerability of tropisetron in combination with dexamethasone in the prevention of delayed platinum-induced nausea and emesis. Cancer 1,1022–1032 (1998).
   Google Scholar
• Van Belle SJP, Cocqut V, Bleiberg H etal Optimal combination therapy with Navoban (tropisetron) in patients with incomplete control of chemotherapy induced nausea and vomiting. Anticancer Drugs 6\(Suppl. 1), 22–30 (1995).
   Google Scholar
• Schmidt M, Sorbe B, Hogberg T etal Efficacy and tolerability of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin. Ann. Oncol 4 (Suppl. 3), 31–34 (1993).
   Google Scholar
• Koivuranta M, Laara E, Snare L, Alahuhta S. A survey of postoperative nausea and vomiting. Anaesthesia 52,443–449 (1997).
   PubMed Web of Science ®Google Scholar
• Apfel CC, Laara E, Koivuranta M, Greim CA, Roewer N. A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology 91,693–700 (1999).
   Google Scholar
• Trani& MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part I. Efficacy and harm of antiemetic interventions and methodological issues. Acta. Anaesthesia" Land. 45,4-13 (2001).
   Google Scholar
• •Gives an overview of the evidence from systematic reviews concerning the treatment and prevention of postoperative nausea and vomiting. They compare the efficacy and side effects of all available antiemetic agents found in different studies and recommend different concepts for the prophylaxis of postoperative nausea and vomiting.
   Google Scholar
• Trani& MR. A rational approach to the control of postoperative nausea and vomiting: evidence from systematic reviews. Part II. Recommendations for prevention and treatment and a research agenda. Acta. Anaesthesia" Scand. 45,14-19 (2001).
   Google Scholar
• •Gives an overview of the evidence from systematic reviews concerning the treatment and prevention of postoperative nausea and vomiting. They compare the efficacy and side effects of all available antiemetic agents found in different studies and recommend different concepts for the prophylaxis of postoperative nausea and vomiting.
   Google Scholar
• Trani& MR, Phillips C, Reynolds DJM, McQuay HJ, Moore RA. Cost-effectiveness of ondansetron for postoperative nausea and vomiting. Anaesthesia 54,226-234 (1999).
   Google Scholar
• •Second article that could be found on the subject of the cost-effectiveness of the 5-HT3 antagonist odansetron for the prophylaxis of post operative nausea and vomiting.
   Google Scholar